Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of human diploid cell rabies vaccine using 5-dose versus 2-1-1 4-dose regimens in people aged 10-60 years
CTR20261567Phase 3Active
- Sponsor
- Dalian Yalifeng Biopharmaceutical
- Start
- Apr 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rabies virus inactivated antigen, B in rabies, sponsored by Dalian Yalifeng Biopharmaceutical. Started Apr 2026; status: active.
02
Drugs
rabies virus inactivated antigen, B
03
Conditions
rabies
Beyond the preview
Go deeper on CTR20261567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261567.